KAIST Researchers Uncover How Neurons Deliver RNA to Where It Is Needed
Much like a courier reading an address on a package, neurons must deliver RNA to the precise locations where it is needed. A KAIST research team has discovered how a small chemical modification on RNA acts as a “delivery tag,” helping selected RNAs travel to distant regions of neurons.
The findings provide a basis for investigating RNA “delivery errors” in brain disorders—cases in which RNA is produced normally but fails to reach its intended destination—and may ultimately inform the development of new therapeutic strategies.
KAIST (President Choongsik Bae) announced on September 14 that a research team led by Professor Ki-Jun Yoon of the Department of Biological Sciences has identified a mechanism through which N6-methyladenosine, or m6A, facilitates the transport of specific RNAs to distal axons, the long, cable-like projections of neurons.
Unlike most other cells, neurons have long, highly branched extensions. Axons transmit signals to other neurons, while dendrites receive incoming signals. For the brain to develop and function normally, these structures must grow properly and form appropriate connections.
Because neurons can extend over considerable distances, RNA produced in the cell body may be needed far away, including at the growing tip of an axon. Neurons must therefore identify particular RNAs among thousands of candidates and transport them to the correct subcellular locations.
Just as producing a package does not complete its delivery—the package must also reach the correct address—producing RNA is only part of the process. RNA must arrive at the right place at the right time. However, the mechanisms through which neurons select and transport RNAs over long distances have remained incompletely understood.
The research team found that m6A, a small chemical modification added to RNA, plays an important role in this process. m6A is a modification of adenosine, one of the building blocks of RNA, and is known to influence several aspects of RNA metabolism, including stability and translation. The new study shows that m6A can also function as a molecular “delivery tag” that promotes the transport of specific RNAs to distal regions of neurons.
The researchers first examined mice in which Mettl14, a component of the enzyme complex that installs m6A on RNA, was deleted from developing neurons. In the absence of normal m6A modification, the neurons exhibited impaired axon projection and neurite development. These findings confirmed that m6A plays an important role in the early development of neurons.
The team then used a high-resolution technique known as m6A-SAC-seq to map the precise locations of m6A modifications in RNA from the developing mouse brain at single-nucleotide resolution. The resulting map revealed that RNAs associated with axon development and synapse organization were among those marked by m6A.
The researchers also identified how this “delivery tag” is recognized and connected to the cellular transport machinery. They found that YTHDF2, a protein that recognizes m6A-modified RNA, works with the RNA-binding protein FMRP and the motor protein KIF5C to facilitate the transport of RNA along neuronal processes.
In the delivery analogy, m6A serves as the tag attached to the RNA, YTHDF2 reads the tag, and FMRP and KIF5C help connect the RNA to the cellular machinery that carries it toward its destination.
YTHDF2 has previously been studied primarily for its role in promoting the degradation of RNA that is no longer needed. This study reveals an additional function: in developing neurons, YTHDF2 also helps transport specific RNAs to distal locations rather than simply directing them toward degradation.
The findings offer a new perspective on the study of brain disorders. Research has traditionally focused on whether RNA is produced and maintained correctly. The new results suggest that researchers should also consider whether normally produced RNA is delivered to the correct location within a neuron.
In other words, neurological dysfunction may potentially arise not only from defects in RNA itself, but also from problems with the molecular tags or transport machinery that determine where the RNA travels.
Future studies could investigate whether such RNA delivery errors occur in neurodevelopmental or neurodegenerative disorders and whether they contribute to neuronal dysfunction or disease onset. If such links are established, the findings could eventually support the development of therapeutic approaches that regulate RNA transport and restore the delivery of specific RNAs to their intended locations.
The high-resolution m6A map of the developing nervous system generated in this study may also serve as a valuable resource for examining how RNA modification and intracellular transport change during brain aging and neurodegenerative disease.
“Our study shows that a small chemical modification on RNA does more than regulate RNA stability—it also plays an important role in delivering specific RNAs to the locations where they are needed within neurons,” said Professor Yoon. “We hope these findings will provide a foundation for understanding why RNA may fail to reach its intended destination in brain disorders and for exploring new therapeutic possibilities.”
Bonsang Koo, Dr. Ajeet Kumar, and Huiseon Hwang of the KAIST Department of Biological Sciences contributed equally to the study as co-first authors. The paper was published in Nature Communications on July 30.
Paper title: The m⁶A reader YTHDF2 regulates mRNA transport and axon outgrowth in developing neurons
DOI: 10.1038/s41467-026-76161-8
Author information: Co-first authors (Bonsang Koo, Ajeet Kumar, Huiseon Hwang); Contributing authors (Minyeong Park, Sung-Min Lee, Ki-Heon Lee, Ji-Hoon Moon, Jaewon Yang, Chan-Woo Park, Saebom Lee, Hee-Jung Jo, Woo-il Kim, Eunji Cho, Hagyeong Lee, Chang-Won Lee, Jae-Sung Woo, Jong Hyuk Yoon, Yoon Ki Kim); Corresponding author (Ki-Jun Yoon)
This work was supported by National Research Foundation of Korea (NRF) grants (2020M3A9E403967022, RS-2024-00332454, RS-2024-00440778, and RS-2026-25488918 to K.-J.Y.) funded by the Korean Ministry of Science and ICT, and Future Planning (MSIP), the POSCOScience Fellowship from the POSCO TJ Park Foundation (to K.-J.Y.), the Young Investigator Grant from the Suh Kyungbae Foundation (to K.-J.Y.), the Korea Brain Research Institute (KBRI) Basic Research Program through the Korea Brain Research Institute, funded by the Ministry of Science and ICT (MSIT) (24-BR-02-03 to J.H.Y).
Vitamin A Derivative Preserves T Cells’ Function as KAIST Points to a New Strategy for Treating Intractable Brain Tumors
Immune cells can become exhausted after prolonged exposure to cancer, gradually losing their ability to attack tumor cells. This phenomenon is particularly pronounced in aggressive brain tumors and can severely limit the effectiveness of immunotherapy. A KAIST research team has now discovered that all-trans retinoic acid (ATRA), a vitamin A derivative, may help prevent such exhaustion and enhance the efficacy of immune checkpoint inhibitors.
KAIST (President Choongsik Bae) announced on September 8 that a research team led by Professor Heung Kyu Lee from the Department of Biological Sciences, in collaboration with researchers from Seoul St. Mary's Hospital, and Konyang University College of Medicine, has found that all-trans retinoic acid (ATRA), a form of active vitamin A metabolite, suppresses the "terminal exhaustion" of CD8⁺ T cells that attack cancer cells within brain tumors, and can enhance the effect of anti-PD-1 immunotherapy. Anti-PD-1 is a leading immuno-oncology drug (immune checkpoint inhibitor).
Glioblastoma is a representative form of intractable brain cancer that frequently recurs even after surgery, radiation, and chemotherapy. Immune checkpoint inhibitors have shown only limited effect against the disease. One key reason is that immune cells that infiltrate the tumor become exhausted after prolonged combat and lose their functional capacity.
Cells that reach a state of terminal exhaustion in particular lose their ability to kill cancer cells, much like soldiers who have exhausted themselves in prolonged combat. In this state, achieving sufficient therapeutic effect is difficult even with anti-PD-1 therapy, which releases the "brake" cancer cells impose on immune cells.
To address this problem, the research team tried to figure out how to prevent immune cells from reaching total burnout, rather than how to revive the cells. Subsequently, the research team focused on the signaling of ATRA, an active vitamin A metabolite known to regulate cell differentiation and function.
Using an in-vitro model that mimicked the hypoxic, exhaustion-promoting tumor microenvironment of brain tumors, the team induced exhaustion in CD8⁺ T cells. Those conditioned with ATRA progressed to terminal exhaustion at a markedly lower rate. These cells also produced higher levels of immune molecules essential for attacking cancer — including interleukin-2 (IL-2), interferon gamma (IFN-γ), and tumor necrosis factor alpha (TNF-α) — and retained their ability to kill brain tumor cells.
The team also confirmed that ATRA activates WNT/β-catenin signaling within CD8⁺ T cells and increases TCF-1βBD, a TCF-1 isoform important for maintaining T-cell function. In simple terms, the vitamin A metabolite turns on a "function-preserving switch" inside immune cells, helping them avoid complete exhaustion even during prolonged combat with cancer cells.
The effect was also confirmed in mouse glioma models. CD8⁺ T cells conditioned with ATRA maintained better immune function within the tumor, and oral administration of ATRA alone also increased both the number and function of tumor-infiltrating CD8⁺ T cells. As tumor burden decreased, survival was also extended. Notably, in a model of recurrent brain tumors, anti-PD-1 immunotherapy alone showed only limited effect, but combining it with ATRA substantially improved tumor suppression and long-term survival outcomes.
In other words, if anti-PD-1 therapy releases the "brake" imposed on immune cells, ATRA keeps their "battery" from running completely dead. By combining the two approaches, the researchers propose a new combination-therapy strategy that could help overcome the limitations of existing immunotherapy.
The team also analyzed publicly available human glioblastoma datasets. In single-cell transcriptomic data from patients treated with anti-PD-1 therapy, CD8⁺ T cells from responders showed higher retinoic-acid-responsive and WNT signaling gene signatures than those from non-responders. Separately, in an immunotherapy-naïve glioblastoma cohort, patients with a higher proportion of retinoic-acid-responsive CD8⁺ T cells showed significantly better overall survival. The team noted that this study does not directly demonstrate ATRA's therapeutic efficacy in patients, and that further clinical research will be needed to confirm appropriate administration methods, dosages, and combination effects with immunotherapy drugs before it can be applied to actual brain tumor treatment.
Professor Heung Kyu Lee said, "Glioblastoma is one of the cancers most resistant to immunotherapy, because immune cells within the tumor readily become exhausted." He added that the study is meaningful for presenting a molecular mechanism by which active vitamin A signaling helps prevent the terminal exhaustion of CD8⁺ T cells while preserving their anti-cancer function. He also noted that future work validating more precise delivery methods or combination strategies could establish this as a new approach for improving the responsiveness of immunotherapy against intractable brain tumors.
The study was conducted with Dr. In Kang, a postdoctoral researcher in KAIST's Department of Biological Sciences, as first author, and Professor Heung Kyu Lee as corresponding author. Professor Jae-Byum Chang from KAIST's Department of Materials Science and Engineering, Professor Sung Ki Lee from Konyang University College of Medicine, and Professor Stephen Ahn from Seoul St. Mary's Hospital also participated in the research. The findings were published on August 26 in the international journal Signal Transduction and Targeted Therapy.
Paper title: All-trans retinoic acid suppresses CD8⁺ T-cell terminal exhaustion and potentiates anti-PD-1 therapy in glioblastoma
DOI: 10.1038/s41392-026-02852-9
This work was supported by National Research Foundation of Korea grants (RS-2023-NR077244, RS-2024-00439735, RS-2026-25509011 to H.K.L. and RS-2024-00352668 to S.A.). This study was also supported by the Samsung Science and Technology Foundation (SSTF-BA1902-05 to H.K.L.), Republic of Korea. This research was also supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (RS-2023-00302794 to J.B.C.).
Neural Implant in Korea Remotely Controlled from the United States, Bringing Brain Research into the IoT Era
A researcher in Chicago remotely controls a miniaturized brain implant in Daejeon, Korea — over the internet. Korean researchers have developed a wireless device that can deliver drugs and light to precisely modulate targeted neurons from anywhere in the world. The technology is expected to overcome the constraints of distance and location, supporting long-term studies of brain disorders and the future development of therapeutic devices.
KAIST (President Choongsik Bae) announced on August 27 that a research team led by Professor Jae-Woong Jeong from the School of Electrical Engineering, in collaboration with Professor Wha Young Kim's team at Yonsei University College of Medicine, has developed an IoT-enabled wireless neural implant that integrates drug delivery, optical stimulation, wireless communication, and internet-based remote control into a single miniaturized device.
Conventional studies involving optical stimulation or drug delivery to the brain often required bulky equipment connected by wires, restricting the natural movement of experimental animals. Even wireless devices had their own limitations, often requiring researchers to operate them at close range, thereby restricting experimental flexibility and introducing the so-called “observer effect”.
To overcome these limitations, the research team developed the brain implant with IoT connectivity. Even without being physically present in the laboratory, researchers can remotely administer drugs or stimulate specific brain neurons with light in real time via the internet. The device can also be programmed to operate automatically at a preset time.
The device is about the size of a sugar cube and is designed not to interfere with the animal's natural behavior. Researchers no longer need to repeatedly approach or handle equipment near the animal, reducing the stress caused by a researcher's presence, which can otherwise affect the animal's behavior and bias experimental results.
The implant contains a microfluidic system that precisely delivers drugs to a targeted region of the brain, as well as a micro-LED that enables optical control of specific neurons. Drug delivery and optical stimulation can be controlled independently, or the two functions can be combined.
The drug reservoir is designed to be magnetically detachable. Even after the drug is depleted, researchers can replace or refill the reservoir without the need for additional implantation surgery, enabling long-term, repeated experiments.
The research team implanted the device in rats and verified its performance over a four-week period. In particular, a researcher in Chicago successfully operated the brain implant in Daejeon, Korea, in real time via the internet, demonstrating that the device can operate reliably over intercontinental distances.
The team also conducted an experiment in which cocaine was wirelessly administered to a rat's brain while specific neurons were simultaneously stimulated with light. The results showed that addiction-related behavioral responses could be suppressed, demonstrating the potential of combining drug delivery and optical stimulation for neural circuit research.
By eliminating the need for researchers to operate equipment directly beside experimental animals, this technology enables long-term studies of the relationship between brain circuits and behavior under naturalistic conditions. It is expected to be useful for studying conditions that involve long-term changes in neural circuit function and behavior, such as addiction, depression, and neurodegenerative diseases.
The technology could ultimately pave the way for intelligent implantable medical devices that combine brain-state sensing with AI to deliver drugs or neural stimulation precisely when needed.
Professor Jae-Woong Jeong from KAIST said, “This technology transforms wireless brain implants that use light and drugs from short-range control tools into IoT-based brain engineering platforms capable of long-term, automated, and remote experimentation.” He added, “In the long term, it could contribute to the development of intelligent implantable medical devices for the diagnosis and treatment of brain disorders.”
Professor Wha Young Kim from Yonsei University said, “This platform allows researchers to remotely and precisely control specific brain circuits over extended periods while animals move freely under naturalistic conditions.” She added, “It is expected to become an important tool for identifying causal relationships between neural circuits and behavior in disease models such as addiction, depression, and neurodegenerative disorders.”
Eun Young Jeong, a doctoral student in KAIST's School of Electrical Engineering, and Jong Woo Park, a doctoral student at Yonsei University College of Medicine, served as co-first authors. The study was published on July 29 in the international journal Science Advances.
Paper title: IoT-enabled wireless neural implant for chronic, programmable neuropharmacology and optogenetics,
DOI: 10.1126/sciadv.aee8648
This research was supported by the Mid-Career Researcher Program and Basic Research Laboratory Program of the National Research Foundation of Korea, funded by the Ministry of Science and ICT, as well as the Industrial Technology Alchemist Project of the Ministry of Trade, Industry and Energy.
KAIST Develops Core Technology to Reverse Biological Changes Once Thought Irreversible, Opening New Possibilities for Aging and Cancer Research
Once a cell has locked into an abnormal state — the way cancer cells do — can it ever be restored back to normal? A KAIST research team has identified the ‘molecular lock’ that keeps cells trapped in an altered state, opening a new path toward releasing that lock and reversing a cell’s fate.
KAIST (President Choongsik Bae) announced on the 21st of August that a research team led by Professor Kwang-Hyun Cho of the Department of Bio and Brain Engineering has, for the first time, identified the causal circuits responsible for irreversibility in intracellular molecular networks and developed a fundamental control technology called ROOT that can regulate these circuits and restore biological states to their original condition.
Cells in the human body change their state in response to external stimuli. In many cases, however, these state changes are irreversible, in the sense that cells do not return to their original state even after the stimulus disappears.
Irreversibility is essential for maintaining normal biological processes, such as a cell differentiating into one with a specific function. At the same time, it can also drive disease progression — for example, in epithelial–mesenchymal transition, which gives cancer cells the ability to migrate into and invade surrounding tissue.
Complicating matters, the circuits that maintain these state changes inside a cell are highly intricate: more than a thousand positive feedback loops are woven throughout the network, in which one molecule activates a series of other molecules that in turn reactivate the original molecule. This is similar to the feedback screech produced when a microphone is placed next to a speaker, where a sound repeatedly amplifies itself. Even a change that starts with an external stimulus can persist after the stimulus is gone, simply because the cell’s own molecules keep reinforcing one another. Until now, it has been extremely difficult to determine which of these countless circuits is actually responsible for locking a cell into an irreversible state.
To solve this problem, the team developed ROOT technology, short for Revelation Of the Original circuit of irreversible Transition, which works by representing intracellular regulatory processes as computational logic models and analyzing them through systems biology techniques. Using ROOT, the research team successfully simulated the process in which cells maintain a signal even after an external stimuli is removed, allowing them to identify a set of core circuits that cause irreversibility, which they defined as the “irreversibility kernel.”
Going beyond identifying the cause, the team also proposed two groundbreaking control strategies.
The first, “resetting control,” restores a cell to its state before the change while leaving the cell’s underlying irreversible property intact — comparable to leaving the lock itself in place, but opening the locked door and returning to the starting point.
The second, “reversing control,” removes the source of irreversibility itself, allowing a cell to move freely between different states — comparable to disabling the mechanism that automatically locks a door each time it closes, so that afterward the door can be opened and closed again.
The team applied the new technique to various biological models, including B-cell differentiation, epithelial–mesenchymal transition in lung cancer, and enterocyte and beta-cell differentiation models based on single-cell transcriptome data, in which the ROOT method accurately identified causal circuits that matched known cell-fate determinants. The team also proposed more effective resetting control strategies, demonstrating that the method can be broadly applied even to models built from real experimental data.
Rather than simply removing cells that have become fixed in an abnormal state, as in cancer or aging, the technology is expected to help identify and control the core circuits that keep cells trapped in that state, enabling new treatment strategies that restore cells to a normal condition.
Professor Kwang-Hyun Cho said, “The core achievement of this study is identifying the causal circuits behind cells that, once changed, do not return to their original state, and developing a technology to control these circuits and restore cells to their previous condition.” He added, “We expect this technology to be used in developing new treatment strategies that restore abnormally fixed cell states — such as those seen in cancer and aging — back to normal.”
This study was co-led by Dr. Jongwan Kim and Dr. Seong-Hoon Jang of KAIST’s Department of Bio and Brain Engineering as co-first authors, with participation from Dr. Jonghoon Lee and Ph.D. student Corbin Hopper. The research was published on August 13 in Proceedings of the National Academy of Sciences of the United States of America (PNAS), one of the world’s leading scientific journals.
Paper title: The structural origin of irreversible transitions in biological networks,
DOI: https://doi.org/10.1073/pnas.2600800123
This research was supported by the Mid-Career Researcher Program and the Basic Research Laboratory Program of the National Research Foundation of Korea, funded by the Ministry of Science and ICT.
KAIST Uncovers the “Hidden Key” to Immunotherapy for Intractable Brain Tumors
Researchers have uncovered a clue to why immune checkpoint inhibitors—cancer therapies that release the immune “brakes” exploited by tumors to evade attack—show limited efficacy in some brain tumors. A KAIST research team found that B cell and antibody responses initiated in tumor-draining lymph nodes, rather than T cells alone, are critical to the antitumor effects of anti-CTLA-4 therapy, opening a new avenue for treating intractable brain tumors.
KAIST (President Choongsik Bae) announced on the 19th of July that a research team led by Professor Heung Kyu Lee from the Department of Biological Sciences has identified a previously unrecognized immune mechanism through which anti-CTLA-4, a type of immune checkpoint inhibitor, promotes B-cell responses in tumor-draining lymph nodes, thereby helping the immune system attack brain tumors.
Glioblastoma is one of the most aggressive malignant brain tumors, with frequent recurrence and a poor prognosis even after surgery and radiation therapy. Immune checkpoint inhibitors, which restore the ability of immune cells to attack cancer cells, have produced substantial therapeutic benefits in various cancers. However, their effectiveness in glioblastoma has remained limited because of the highly immunosuppressive environment surrounding the tumor.
Researchers have traditionally regarded T cells—immune cells that can directly attack cancer cells—as the primary target of immune checkpoint inhibitors. B cells, meanwhile, are well known for producing antibodies following infection or vaccination, but their role in brain tumor immunotherapy has remained largely unexplored. The research team therefore investigated whether anti-CTLA-4 could influence B-cell responses as well as T-cell responses.
The findings challenged the prevailing T-cell-centered view. In mouse glioma models, anti-CTLA-4 treatment reduced tumor burden and significantly prolonged survival. However, these therapeutic effects were largely lost in mice lacking B cells, demonstrating that B cells are required for the efficacy of anti-CTLA-4 treatment in these models.
The team also identified where B cells played their key role. Rather than being prominent in the brain, where the tumor cells were located, the response increased markedly in the Deep Cervical Lymph Nodes, which are located deep in the neck and receive lymphatic drainage from the brain. In particular, germinal center B cells and T follicular helper cells, both of which are important for antibody formation, increased together in these lymph nodes. This was accompanied by an increase in immunoglobulin G, or IgG, responses. IgG is a major class of antibody that can recognize cancer cells as targets and help immune cells eliminate them.
The resulting IgG antibodies bound to the surface of glioma cells, helping macrophages—immune cells that engulf foreign substances and cancer cells—remove the tumor cells more effectively.
The research team also examined this process directly in vivo. Using a specialized dual-reporter glioma model expressing the red fluorescent protein mCherry and the green fluorescent protein EGFP, the researchers successfully visualized tumor-infiltrating phagocytes actively engulfing glioma cells following anti-CTLA-4 treatment.
The study provides the first functional evidence that B-cell immune responses—previously known mainly for their roles in infection and vaccination—can be a key factor determining the effectiveness of immunotherapy for hard-to-treat brain tumors. It also expands the conventional T-cell-centered framework of cancer immunotherapy by showing that treatment efficacy can be strongly shaped by immune responses originating not only within the tumor, but also in tumor-draining lymph nodes outside it.
Yumin Kim, a postdoctoral researcher in the KAIST Department of Biological Sciences, served as the first author of the study, with Professor Heung Kyu Lee serving as the corresponding author. Professor Ji Eun Oh from the KAIST Graduate School of Medical Science and Engineering also contributed to the research. The findings were published on July 10 in Science Immunology.
Paper title: The efficacy of immunotherapy in glioma requires distal B-cell responses in tumor-draining lymph nodes
DOI: 10.1126/sciimmunol.adz2494
Authors: Yumin Kim, In Kang, Byeong Hoon Kang, Won Hyung Park, Chae Won Kim, Hyun-Jin Kim, Jeongwoo La, Myoung Seung Kwon, Sang Hee Park, Seo Hyeon Im, Hyeon Cheol Kim, Keun Bon Ku, Minji Kim, and Ji Eun Oh from KAIST, with Heung Kyu Lee from KAIST as the corresponding author.
This research was supported by National Research Foundation of Korea grants RS-2023-NR077244 (to H.K.L.), RS-2024-00439735 (to H.K.L.), RS-2024-00411928 (to Y.K.), RS-2025-00517107 (to J.E.O.), and RS-2026-25509011 (to H.K.L.). This study was also supported by Samsung Science and Technology Foundation grants SSTF-BA1902-05 (to H.K.L.) and SSTF-BA2201-11 (to J.E.O.).
KAIST Begins Developing the World’s First Brain-to-Robot Technology, Moving Robots by Thought and Sending Sensation Back to the Brain
KAIST researchers have begun developing a next-generation brain-robot interface platform that uses human brain signals to control an exoskeleton in real time and sends the tactile and force information sensed by the robot back to the brain.
KAIST, led by President Kwang-Hyung Lee, announced on the 25th that research teams led by Professors Kyoungchul Kong and Jung Kim of its Department of Mechanical Engineering, together with Angel Robotics Co., Ltd., have launched the world’s first bidirectional “Brain-to-Robot” system as a flagship initiative of the Korea Medical Device Development Fund (KMDF). The project runs from April 2026 to December 2032.
Professor Kyoungchul Kong is a world-renowned wearable-robotics researcher who founded Angel Robotics, a developer of walking-assist exoskeletons, and led his team to back-to-back gold medals at Cybathlon, the international competition for assistive technologies for people with disabilities. Professor Jung Kim is a globally recognized researcher who received the Scientist and Engineer of the Month Award for his work on robotic skin. Together, the two teams have formed a consortium to develop a Brain-to-Robot platform that merges neural interfaces with exoskeleton robotics.
Brain interface technologies that let users move a cursor or operate a smartphone with brain signals have already reached the stage of human clinical trials, and U.S. companies such as Neuralink and Synchron are accelerating their development. Existing approaches, however, have struggled to link actual movement and sensory feedback at the same time. They have also concentrated largely on advancing signal decoding itself, without clearly defining the target of control, namely what the brain signals actually drive and what kind of sensory information is returned.
Brain-to-Robot is designed to overcome these limitations head-on. It sets the exoskeleton itself as the control target: brain signals read the user’s movement intentions to drive the robot, and at the same time the robot’s sensory readings are delivered back to the brain. These readings include ground reaction force (the force the floor exerts on the foot), joint torque (rotational force at the joints), and tactile information. The aim is a complete bidirectional interface.
According to the research team, no fully bidirectional Brain-to-Robot system that combines exoskeleton control with sensory feedback has yet been reported anywhere in the world, and the project is expected to mark a turning point in brain interface technology.
Within this system, the KAIST teams are responsible for the core technologies. Professor Kong’s team will develop wearable-robot control and AI-based interpretation of movement intention, and will design a somatosensory interface, a system for transmitting bodily sensory information, that delivers the robot’s sensory data accurately to the Brain Chip, the semiconductor that processes brain signals.
Professor Kim’s team will develop robotic skin that senses in place of impaired sensation for people with disabilities, along with AI-based interpretation of somatosensory information.
The teams will also develop AI-based encoding and decoding algorithms that turn brain signals into robot commands and send the robot’s sensory information back to the brain. A key challenge is processing hundreds of channels of cortical signals, the neural signals generated in the cerebral cortex, while stably maintaining an ultra-low-latency closed loop, a control cycle in which signals are exchanged continuously in real time.
Commercialization of the flagship project will be led by Angel Robotics (KOSDAQ: 455900), the company founded by Professor Kong. The team plans to pursue full-cycle commercialization, from regulatory approval by the Ministry of Food and Drug Safety through to real-world deployment.
“If this technology succeeds, it will open a new rehabilitation paradigm in which people with quadriplegia can move beyond the hospital to walk on their own, pick up objects, and even feel sensation at their fingertips in everyday life,” Professor Kong said.
The research team stressed that, because this is an unprecedented and highly complex convergence technology never attempted at home or abroad, long-term safety, clinical validation, and a regulatory approval framework must advance in parallel with the technology itself. To reach the global market, they added, safety and efficacy testing, the accumulation of clinical evidence, a risk-management system, protection of brain-signal data, cybersecurity, and ethical review must all be addressed in an integrated way.
Meanwhile, KAIST is conducting a wide range of fundamental research in the field of brain interfaces. A research team led by Professor Hyung-Soon Park of the Department of Mechanical Engineering is studying wearable rehabilitation robot technologies based on neural intention-recognition interfaces, which identify users’ movement intentions from brain signals, for the effective treatment of neurological disorders. A research team led by Professor Sungho Cho of the School of Computing is developing AI-based brain-signal interpretation technologies.
A research team led by Professor Jihoon Lee of the Department of Brain and Cognitive Sciences is conducting next-generation brain–machine interface research focused on ultra-low-power bio/neural interface circuits, which connect and process biological and neural signals with low power consumption; wireless neural signal measurement technologies, which measure neural signals without wires; and on-device AI-based closed-loop neuromodulation technologies, which use cyclical control structures to exchange signals in real time.
In addition, a research team led by Professor Hyunjoo Lee of the School of Electrical Engineering is conducting research on high-resolution neural signal measurement and precision brain stimulation based on ultra-miniaturized multimodal neural electrodes, which can simultaneously measure and stimulate multiple types of neural signals. A research team led by Professor Minkyu Je of the Department of AI Semiconductor Systems is studying AI-based semiconductor integrated circuits and system technologies for next-generation neural interfaces. A research team led by Professor Jae-Woong Jeong of the School of Electrical Engineering is conducting research on high-precision brain-signal measurement, which precisely measures neural signals generated in the brain, and neuroengineering based on neural stimulation.
“This Brain-to-Robot flagship project is a world-class, highly challenging convergence research initiative led by the teams of Professors Kyoungchul Kong and Jung Kim,” said KAIST President Kwang-Hyung Lee. “KAIST has a wide range of researchers studying fundamental technologies in brain interfaces, AI, semiconductors, and robotics, and based on this foundation, we will lead innovation in next-generation Brain-to-Robot technologies.”
Secret to Drug Addiction Relapse Found: Brain's Addiction Circuit Identified
<(From Left) Dr. Minju Jeong,(UCSD), Prof. Byung Kook Lim (UCSD), Prof. Se-Bum Paik (KAIST)>
Drug addiction carries an extremely high risk of relapse, as cravings can be reignited by minor stimuli even long after one has stopped using. Previously, this phenomenon was attributed to a decline in the function of the prefrontal cortex (PFC), which regulates impulses. However, a joint international research team has recently revealed that the cause of addiction relapse is not a simple decline in brain function, but rather an imbalance in specific neural circuits.
KAIST announced on March 9th that a research team led by Prof. Se-Bum Paik from the Department of Brain and Cognitive Sciences and Prof. Byung Kook Lim from the University of California, San Diego (UCSD) has identified the core principle by which specific inhibitory neurons in the prefrontal cortex regulate cocaine-seeking behavior.
In particular, the research team focused on parvalbumin-positive (PV) inhibitory neurons, which regulate the balance of neural signals by suppressing the activity of other neurons in the brain. They confirmed that these cells act as a "brake gate" that controls excitatory signals in the brain and serve as a crucial factor in determining drug-seeking behavior that emerges after withdrawal.
The prefrontal cortex (PFC) of our brain can properly perform its "braking" function to suppress impulses when excitatory and inhibitory signals are in balance. To investigate how chronic drug exposure disrupts this balance, the research team conducted cocaine administration experiments on mice. During this process, they tracked when inhibitory neurons in the PFC were activated and how they sent signals to downstream brain regions.
The experimental results showed that parvalbumin (PV) cells, which account for about 60-70% of the inhibitory neurons in the PFC, were highly active when the mice attempted to seek cocaine. However, when "extinction training"—training to stop seeking the drug—was conducted, the activity of these cells significantly decreased. This demonstrates that the activity patterns of PV cells are not permanently fixed by addiction but can be readjusted through the extinction process.
<Figure 1. Experimental design illustrating cocaine self-administration and longitudinal tracking of prefrontal cortical neural activity during cocaine-seeking behavior>
The research team confirmed that artificially suppressing PV cell activity significantly reduced cocaine-seeking behavior in mice. Conversely, activating these cells caused the drug-seeking behavior to persist even after the extinction process. This effect was specifically observed in drug-addiction behavior and did not appear with general rewards like sugar water. Furthermore, this phenomenon was not observed in somatostatin (SOM) cells—another type of inhibitory neuron—indicating that PV cells selectively regulate drug addiction behavior.
<Figure 2. Comparison of single-neuron activity, population activity patterns, and behavioral modulation of prefrontal inhibitory neurons across different stages of cocaine-seeking behavior>
The team also identified the specific brain circuit through which these PV cells operate. Signals originating from the prefrontal cortex are transmitted to the reward circuit of the Ventral Tegmental Area (VTA), a key brain region related to reward. This pathway emerged as the central channel for regulating addiction behavior, determining whether or not to seek the drug again. In this process, PV neurons act as a "regulatory switch," controlling the flow of signals to influence dopamine signaling and deciding whether to maintain or suppress addictive behavior.
In short, the study revealed that addiction relapse is not due to an overall functional decline of the prefrontal cortex, but is determined by whether PV neurons regulate the neural pathway connecting the PFC to the reward circuit.
<Figure 3. Schematic illustrating the prefrontal–reward circuit mechanism that determines drug-seeking behavior>
Prof. Se-Bum Paik stated, "This research shows that drug addiction is a circuit-level problem arising from a collapse in the regulatory balance of specific neurons and downstream neural circuits. The discovery that parvalbumin (PV) cells act as a 'gate' for addictive behavior will provide a crucial lead for developing precision-targeted treatment strategies in the future."
This study was led by Dr. Minju Jeong (UCSD) as the first author, with Prof. Byung Kook Lim (UCSD) and Prof. Se-Bum Paik (KAIST) serving as co-corresponding authors. The findings were published online on February 26 in Neuron, a premier journal in the field of neuroscience.
Paper Title: Distinct Interneuronal Dynamics Selectively Gate Target-Specific Cortical Projections in Drug Seeking
DOI: 10.1016/j.neuron.2026.01.002
Full Author List: Minju Jeong, Seungdae Baek, Qingdi Wang, Li Yao, Eun Ji Lee, Arturo Marroquin Rivera, Joann Jocelynn Lee, Hyeonseok Jang, Dhananjay Bambah-Mukku, Christine Hyun-Seung Mun, Tyler Boesen, Sumit Nanda, Cheol Ryong Ku, Hong-wei Dong, Benoit Labonté, Se-Bum Paik, and Byung Kook Lim.
This research was conducted with the support of the Basic Research Program in Science and Engineering of the National Research Foundation of Korea.
KAIST Develops mRNA Platform That Remains Effective Even in Aging and Obesity
<(From Left) Dr. Subin Yoon, Ph.D candidate Hyeonggon Cho, Prof. Jae-Hwan Nam, Prof. Young-suk Lee>
Since the COVID-19 pandemic, mRNA vaccines have gained attention as a next-generation pharmaceutical technology. mRNA therapeutics work by delivering genetic instructions that enable cells to produce specific proteins for therapeutic effects. However, their efficacy has been reported to decline in elderly individuals or patients with obesity. To address this limitation, Korean researchers have newly designed a key regulatory region of mRNA that improves therapeutic protein production efficiency, developing a next-generation mRNA platform that maintains effectiveness even in aging and obesity conditions.
KAIST (President Kwang Hyung Lee) announced on the 10th of March that a joint research team led by Professor Young-suk Lee of the Department of Bio and Brain Engineering and Professor Jae-Hwan Nam of The Catholic University of Korea (President Jun-Gyu Choi) has developed a new mRNA platform by precisely designing the sequence of the 5′ untranslated region (5′UTR)*, a key regulatory region of mRNA.*5′ untranslated region (5′UTR): A region of mRNA that initiates and regulates protein production. The design of this region influences both the amount and speed of protein synthesis.
The research team analyzed large-scale bioinformatics datasets to identify 5′UTR sequences that enable proteins to be produced more efficiently across diverse cellular environments. When applied, the designed sequences significantly enhanced protein production and immune responses even in preclinical models of aging and obesity.
mRNA is a long single-stranded RNA molecule that serves as the blueprint for producing proteins required by the body. It consists of several components: the 5′UTR, which initiates and regulates the rate of protein production; the coding sequence (CDS), which contains the genetic information for a specific protein; the 3′ untranslated region (3′UTR), which helps maintain mRNA stability within cells; and the poly(A) tail, which further enhances stability and supports protein synthesis.
Among these components, the 5′UTR and 3′UTR do not determine the type of protein produced, but they play a critical role in regulating how efficiently the protein is synthesized. For this reason, these regions are receiving increasing attention as key bioengineering platforms for improving the performance of various mRNA therapeutics, including vaccines and treatments.
<Schematic Diagram of mRNA Therapeutic Design and Validation Using Bioinformatics>
To identify highly efficient 5′UTR sequences capable of promoting protein production across multiple tissues and cellular environments, the team conducted an integrated analysis of large-scale biological datasets. This included multiple analytical approaches such as RNA sequencing (RNA-seq) for analyzing gene activity across tissues, single-cell RNA sequencing (scRNA-seq) for examining gene expression at the individual cell level, and ribosome profiling (Ribo-seq) for measuring actual protein translation efficiency.
The researchers also focused on the fact that in aging or obesity conditions, cells often experience high levels of stress—particularly oxidative stress—which can reduce their ability to synthesize proteins. When the newly designed mRNA therapeutics were applied to preclinical models of aging and obesity, the results showed significantly improved protein production and immune responses compared with existing approaches. This research is expected to be applicable not only to mRNA vaccines but also to a wide range of biopharmaceutical technologies, including gene therapies and immunotherapies.
<Multimodal Bio–Big Data Analysis–Based mRNA Therapeutic Design (AI-Generated Image)>
Professor Young-suk Lee of KAIST Department of Bio and Brain Engineering stated, “This study identified a design strategy that enables mRNA to produce proteins more efficiently by analyzing large-scale biological data,” adding, “This technology will provide an important foundation for ensuring that mRNA vaccines and therapeutics remain effective even in environments where drug efficacy may decline, such as in elderly or obese patients.”
In this study, Dr. Subin Yoon from The Catholic University of Korea and doctoral candidate Hyeonggon Cho from KAIST participated as co-first authors. The research findings were published online on January 2 in the internationally renowned journal Molecular Therapy (IF = 12.0), a leading journal in gene and cell therapy.
(Paper title: ”Designing 5′UTR sequences improves the capacity of mRNA therapeutics in preclinical models of aging and obesity” DOI: https://doi.org/10.1016/j.ymthe.2025.12.060)
This research was supported by the Excellent Young Researcher Program and the Bio-Medical Technology Development Program of the National Research Foundation of Korea funded by the Ministry of Science and ICT, the Infectious Disease Response Innovative Technology Support Program of the Ministry of Food and Drug Safety, and the Infectious Disease Prevention and Therapeutics Technology Development Program of the Korea Health Industry Development Institute.
KAIST Develops Brain-Like AI… Thinks One More Time Even When Predictions Are Wrong
<(From left) Professor Sang Wan Lee, Myoung Hoon Ha, and Dr. Yoondo Sung>
Artificial intelligence now plays Go, paints pictures, and even converses like a human. However, there remains a decisive difference: AI requires far more electricity than the human brain to operate. Scientists have long asked the question, “How can the brain learn so intelligently using so little energy?” KAIST researchers have moved one step closer to the answer.
KAIST (President Kwang Hyung Lee) announced on the 29th that a research team led by Distinguished Professor Sang Wan Lee of the Department of Brain and Cognitive Sciences has developed a new technology that applies the learning principles of the human brain to deep learning, enabling stable training even in deep artificial intelligence models.
Our brain does not passively receive the world. Instead of merely perceiving what is happening in the present, it first predicts what will happen next and, when reality differs from that prediction, adjusts itself to reduce the difference (i.e., prediction error). This is similar to anticipating an opponent’s next move in Go and changing strategy if the prediction turns out to be wrong. This mode of information processing is known as “Predictive Coding.”
< Predictive Coding (PC) Module >
Scientists have attempted to apply this principle to AI, but encountered difficulties. As neural networks become deeper, errors tend to concentrate in specific layers or vanish altogether, repeatedly leading to performance degradation.
The research team mathematically identified the cause of this problem and proposed a new solution. The key idea is simple: instead of predicting only the final outcome, the AI is designed to also predict how its prediction errors will change in the future. The team refers to this as “Meta Prediction.” In simple terms, it is an AI that “thinks once more about its mistakes.” When this method was applied, learning proceeded stably in deep neural networks without halting.
<Analysis of Instability in Predictive Coding Model Errors>
The experimental results were also impressive. In 29 out of 30 experiments, the proposed method achieved higher accuracy than the current standard AI training method, backpropagation. Backpropagation is the representative learning method in which AI “goes backward by the amount of error and corrects it.”
Conventional AI training methods (backpropagation) require tightly interconnected layers, meaning the entire network must be computed and updated simultaneously. In contrast, this new approach demonstrates that, like the brain, large AI models can be effectively trained even when learning occurs in a distributed and partially independent manner.
<Performance Comparison of Predictive Coding Models>
This technology is expected to expand into various fields where power efficiency is critical, including neuromorphic computing, robot AI that must adapt to changing environments, and edge AI operating within devices.
Distinguished Professor Sang Wan Lee stated, “The key to this research is not simply imitating the structure of the brain, but enabling AI to follow the brain’s learning principles themselves,” adding, “We have opened the possibility of artificial intelligence that learns efficiently like the brain.”
This study was conducted with Dr. Myoung Hoon Ha as the first author and Professor Sang Wan Lee as the corresponding author. The paper was accepted to the International Conference on Learning Representations (ICLR 2026) and was published online on January 26.
※ Paper title: “Stable and Scalable Deep Predictive Coding Networks with Meta Prediction Errors”Original paper: https://openreview.net/forum?id=kE5jJUHl9i¬eId=e6T5T9cYqO
This research was supported by the Ministry of Science and ICT and the Institute of Information & Communications Technology Planning & Evaluation (IITP) through the Digital Global Research Support Program (joint research with Microsoft Research), the Samsung Electronics SAIT NPRC Program, and the SW Star Lab Program.
KAIST-Yonsei Team Identifies Origin Cells for Malignant Brain Tumor Common in Young Adults
<Dr. Jung Won Park, (Upper Right) Professor Jeong Ho Lee, Professor Seok-Gu Kang>
IDH-mutant glioma, caused by abnormalities in a specific gene (IDH), is the most common malignant brain tumor among young adults under the age of 50. It is a refractory brain cancer that is difficult to treat due to its high recurrence rate. Until now, treatment has focused primarily on removing the visible tumor mass. However, a Korean research team has discovered for the first time that normal brain cells acquire the initial IDH mutation and spread out through the cortex long before a visible tumor mass harboring additional cancer mutations forms, opening a new path for early diagnosis and treatment to suppress recurrence.
KAIST announced on January 9th that a joint research team led by Professor Jeong Ho Lee from the Graduate School of Medical Science and Engineering and Professor Seok-Gu Kang from the Department of Neurosurgery at Yonsei University Severance Hospital has identified that IDH-mutant gliomas originate from Glial Progenitor Cells (GPCs) present in normal brain tissue.
Glial Progenitor Cells (GPC): Cells that exist in the normal brain and can become the starting point for malignant brain tumors if genetic mutations occur.
Through precise analysis of tumor tissue obtained via extensive resection surgery and the surrounding normal cerebral cortex, the research team discovered that "cells of origin" harboring the IDH mutation already existed within brain tissue that appeared normal to the naked eye.
< Brain-Derived Refractory Brain Tumor Origin Cells (AI-Generated Image) >
This result proves for the first time that malignant brain tumors do not emerge suddenly at a specific point in time, but rather begin within a normal brain and progress slowly over a long period.
The research team then used "spatial transcriptomics"—a cutting-edge analysis technology that shows "which genes are operating where" simultaneously—to confirm that these origin cells with mutations were indeed Glial Progenitor Cells (GPCs) located in the cerebral cortex.
Furthermore, they successfully reproduced the process of brain tumor development in an animal model by introducing the same genetic "driver mutation" found in patients into the GPCs of mice.
This study is a significant expansion of previous research identifying the "origin" of IDH wildtype malignant brain tumors. In 2018, the joint research team led a paradigm shift in brain tumor research by revealing that IDH wildtype glioblastoma, a representative malignant brain tumor, originates not from the tumor body itself, but from neural stem cells in the subventricular zone—the source of new brain cells in the adult brain (Lee et al., Nature, 2018).
The current study clarifies that even though "IDH wildtype glioblastoma" and "IDH-mutant glioma" are both types of brain cancer, their starting cells and points of origin are entirely different, proving that different types of brain tumors have fundamentally different developmental processes.
< Mechanistic Elucidation of Malignant Brain Tumor Development Induced by IDH Mutations and Subsequent Genetic Alterations in Normal Cortical Glial Progenitor Cells >
Professor Seok-Gu Kang (Co-Corresponding Author) stated, "Brain tumors may not start exactly where the tumor mass is visible. A target approach focused on the origin cells and the site of origin according to the brain tumor subtype will serve as a crucial clue to changing the paradigm of early diagnosis and recurrence suppression treatment."
Based on these research results, Sovagen Co., Ltd, a faculty startup from KAIST, is developing an innovative RNA-based drug to suppress the evolution and recurrence of IDH-mutant malignant brain tumors. Additionally, Severance Hospital is pursuing the development of technologies to detect and control early mutant cells in refractory brain tumors through the Korea-US Innovative Result Creation R&D project.
Dr. Jung Won Park (Postdoctoral Researcher at KAIST Graduate School of Medical Science and Engineering), a neurosurgeon and the sole first author of the study, said, "This achievement was made possible by combining KAIST’s world-class basic science research capabilities with the clinical expertise of Yonsei Severance Hospital. The question I kept asking while treating patients—'Where does this tumor originate?'—was the starting point of this research."
The findings were published on January 8th in the world-renowned academic journal Science.
Paper Title: IDH-mutant gliomas arise from glial progenitor cells harboring the initial driver mutation
DOI: 10.1126/science.adt0559
Authors: Jung Won Park (KAIST, First Author), Seok-Gu Kang (Yonsei Severance Hospital, Corresponding Author), Jeong Ho Lee (KAIST, Sovagen, Corresponding Author)
This research was conducted with support from the Suh Kyung-bae Science Foundation, the National Research Foundation of Korea, the Ministry of Science and ICT, the Ministry of Health and Welfare, and the Korea Health Industry Development Institute (Physician-Scientist Training Program).
KAIST Awakens dormant immune cells inside tumors to attack cancer
<(From Left) Professor Ji-Ho Park, Dr. Jun-Hee Han from the Department of Bio and Brain Engineering>
Within tumors in the human body, there are immune cells (macrophages) capable of fighting cancer, but they have been unable to perform their roles properly due to suppression by the tumor. KAIST researchers have overcome this limitation by developing a new therapeutic approach that directly converts immune cells inside tumors into anticancer cell therapies.
KAIST (President Kwang Hyung Lee) announced on the 30th that a research team led by Professor Ji-Ho Park of the Department of Bio and Brain Engineering has developed a therapy in which, when a drug is injected directly into a tumor, macrophages already present in the body absorb it, produce CAR (a cancer-recognizing device) proteins on their own, and are converted into anticancer immune cells known as “CAR-macrophages.”
Solid tumors—such as gastric, lung, and liver cancers—grow as dense masses, making it difficult for immune cells to infiltrate tumors or maintain their function. As a result, the effectiveness of existing immune cell therapies has been limited.
CAR-macrophages, which have recently attracted attention as a next-generation immunotherapy, have the advantage of directly engulfing cancer cells while simultaneously activating surrounding immune cells to amplify anticancer responses.
However, conventional CAR-macrophage therapies require immune cells to be extracted from a patient’s blood, followed by cell culture and genetic modification. This process is time-consuming, costly, and has limited feasibility for real-world patient applications.
To address this challenge, the research team focused on “tumor-associated macrophages” that are already accumulated around tumors.
They developed a strategy to directly reprogram immune cells in the body by loading lipid nanoparticles—designed to be readily absorbed by macrophages—with both mRNA encoding cancer-recognition information and an immunostimulant that activates immune responses.
In other words, in this study, CAR-macrophages were created by “directly converting the body’s own macrophages into anticancer cell therapies inside the body.”
<Figure . Schematic illustration of the strategy for in vivo CAR-macrophage generation and cancer cell eradication via co-delivery of CAR mRNA and immunostimulants using lipid nanoparticles (LNPs)>
When this therapeutic agent was injected into tumors, macrophages rapidly absorbed it and began producing proteins that recognize cancer cells, while immune signaling was simultaneously activated. As a result, the generated “enhanced CAR-macrophages” showed markedly improved cancer cell–killing ability and activated surrounding immune cells, producing a powerful anticancer effect.
In animal models of melanoma (the most dangerous form of skin cancer), tumor growth was significantly suppressed, and the therapeutic effect was shown to have the potential to extend beyond the local tumor site to induce systemic immune responses.
Professor Ji-Ho Park stated, “This study presents a new concept of immune cell therapy that generates anticancer immune cells directly inside the patient’s body,” adding that “it is particularly meaningful in that it simultaneously overcomes the key limitations of existing CAR-macrophage therapies—delivery efficiency and the immunosuppressive tumor environment.”
This research was led by Jun-Hee Han, Ph.D., of the Department of Bio and Brain Engineering at KAIST as the first author, and the results were published on November 18 in ACS Nano, an international journal in the field of nanotechnology.
※ Paper title: “In Situ Chimeric Antigen Receptor Macrophage Therapy via Co-Delivery of mRNA and Immunostimulant,” Authors: Jun-Hee Han (first author), Erinn Fagan, Kyunghwan Yeom, Ji-Ho Park (corresponding author), DOI: 10.1021/acsnano.5c09138
This research was supported by the Mid-Career Researcher Program of the National Research Foundation of Korea.
Presenting a Brain-Like Next-Generation AI Semiconductor that Sees and Judges Instantly
< (From left) Professor Sanghun Jeon, Ph.D candidate Seungyeob Kim, Postdoctoral researcher Hongrae Cho, Ph.D candidates Sang-ho Lee and Taeseung Jung, and M.S candidate Seonjae Park >
With the advancement of Artificial Intelligence (AI), the importance of ultra-low-power semiconductor technology that integrates sensing, computation, and memory into a single unit is growing. However, conventional structures face challenges such as power loss due to data movement, latency, and limitations in memory reliability. A Korean research team has drawn international academic attention by presenting core technologies for an integrated ‘Sensor–Compute–Store’ AI semiconductor to solve these issues.
KAIST announced on December 31st that Professor Sanghun Jeon’s research team from the School of Electrical Engineering presented a total of six papers at the ‘International Electron Devices Meeting (IEEE IEDM 2025)’—the world’s most prestigious semiconductor conference—held in San Francisco from December 8 to 10. Among these, the papers were simultaneously selected as a Highlight Paper and a Top Ranked Student Paper.
Highlight Paper: Monolithically Integrated Photodiode–Spiking Circuit for Neuromorphic Vision with In-Sensor Feature Extraction [Link: https://iedm25.mapyourshow.com/8_0/sessions/session-details.cfm?scheduleid=255]
Top Ranked Student Paper: A Highly Reliable Ferroelectric NAND Cell with Ultra-thin IGZO Charge Trap Layer; Trap Profile Engineering for Endurance and Retention Improvement [Link: https://iedm25.mapyourshow.com/8_0/sessions/session-details.cfm?scheduleid=124]
The research on the M3D integrated neuromorphic vision sensor, selected as a highlight paper, is a semiconductor that stacks the human eye and brain within a single chip. Simply put, the sensors that detect light and the circuits that process signals like a brain are made into very thin layers and stacked vertically in one chip, implementing a structure where the process of 'seeing' and 'judging' occurs simultaneously.
Through this, the research team completed the world's first "In-Sensor Spiking Convolution" platform, where AI computation technology that "sees and judges at the same time" takes place directly within the camera sensor.
< Figure 1. Summary of research on vertically stacked optical signal-to-spike frequency converter for AI >
< Figure 2. Representative diagram of the development of a 2T-2C near-pixel analog computing cell based on oxide thin-film transistors >
Previously, this technology required several stages: capturing an image (sensor), converting it to digital (ADC), storing it in memory (DRAM), and then calculating (CNN). However, this new technology eliminates unnecessary data movement as the calculation happens immediately within the sensor. As a result, it has become possible to implement real-time, ultra-low-power Edge AI with significantly reduced power consumption and dramatically improved response speeds.
Based on this approach, the research team presented six core technologies at the conference covering all layers of AI semiconductors, from input to storage. They simultaneously created neuromorphic semiconductors that operate like the brain using much less electricity while utilizing existing semiconductor processes, along with next-generation memory optimized for AI.
First, on the sensor side, they designed the system so that judgment occurs at the sensor stage rather than having separate components for capturing images and calculating. Consequently, power consumption decreased and response speeds increased compared to the conventional method of taking a photo and sending it to another chip for calculation.
< Figure 3. Schematic diagram of a next-generation biomimetic tactile system using neuromorphic devices >
< Figure 4. Representative diagram of NC-NAND development research based on Ultra-thin-Mo and Sub-3.5 nm HZO >
Furthermore, in the field of memory, they implemented a next-generation NAND flash that uses the same materials but operates at lower voltages, lasts longer, and can store data stably even when the power is turned off. Through this, they presented a foundational technology that satisfies the requirements for high-capacity, high-reliability, and low-power memory necessary for AI.
< Figure 5. Representative diagram of next-generation 3D FeNAND memory development research >
< Figure 6. Representative diagram of research on charge behavior characterization and quantitative analysis methodology for next-generation FeNAND memory >
Professor Sanghun Jeon, who led the research, stated, "This research is significant in that it demonstrates that the entire hierarchy can be integrated into a single material and process system, moving away from the existing AI semiconductor structure where sensing, computation, and storage were designed separately." He added, "Moving forward, we plan to expand this into a next-generation AI semiconductor platform that encompasses everything from ultra-low-power Edge AI to large-scale AI memory."
Meanwhile, this research was conducted with support from basic research projects of the Ministry of Science and ICT and the National Research Foundation of Korea, as well as the Center for Heterogeneous Integration of Extreme-scale & Property Semiconductors (CH³IPS). It was carried out in collaboration with Samsung Electronics, Kyungpook National University, and Hanyang University.